Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 5

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 $— 

    Issuance
    of ordinary shares (1)(2) 
     9,857,143  
     986  
     —  
     34,014  
     —  
     35,000 

    Net
    loss 
     —  
     —  
     —  
     —  
     (54,931) 
     (54,931)

    Balance
    – June 30, 2024 
     9,857,143  
    $986  
    $—  
    $34,014  
    $(54,931) 
    $(19,931)

    Net
    loss 
     —  
     —  
     —  
     —  
     (144,928) 
     (144,928)

    Balance
    – September 30, 2024 
     9,857,143  
    $986  
    $—  
    $34,014  
    $(199,859) 
    $(164,859)

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option were not exercised in full by the underwriters (Note 5). In February 2025, the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 6).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor held 9,857,143 ordinary shares. All share and per share data has been retrospectively presented. 

The
accompanying notes are an integral part of the unaudited financial statements.

3

DRUGS
MADE IN AMERICA ACQUISITION CORP.

STATEMENTS
OF CASH FLOWS

(UNAUDITED)

    Nine Months
    Ended September 30,  
    For the
    Period from May 23, 2024 (inception) through September 30, 

    2025  
    2024 
  
    Cash
    Flows from Operating Activities: 

    Net
    income (loss) 
    $5,727,685  
    $(